# Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

> **NCT00882518** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 388 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)
- **DRUG:** Chlorpromazine

## Key facts

- **NCT ID:** NCT00882518
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2012-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882518, "Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00882518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*